Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Recruiting 2Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 5Non-Muscle Invasive Bladder Neoplasms 2Prostatic Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1High-risk Non-muscle Invasive Bladder Cancer 1Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × disitamab vedotin × Genitourinary × Clear all
NCT04879329 2026-04-21

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Seagen Inc.

Phase 2 Recruiting
372 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Seagen Inc.

Phase 3 Active not recruiting
412 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd.

Phase 3 Recruiting
452 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05912205 2023-06-22

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05723991 2023-02-13

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Tongji Hospital

Phase 4 Unknown
36 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡